ArticleFrontiers in oncology2026
Case Report: Durable response to mirvetuximab soravtansine in a patient with platinum-sensitive ovarian cancer and a diagnosis of myelodysplastic syndrome.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: High-grade serous ovarian cancer is one of the most lethal malignancies in women, typically diagnosed at an advanced stage, treated with debulking surgery, platinum-based chemotherapy and maintenance therapy, and associated with a high risk of recurrence even after optimal treatment. Myelodysplastic syndrome is a rare but serious haematological disease which can occur after exposure to chemotherapy or PARP inhibitor therapy. Treatment of recurrent disease in patients who develop Myelodysplastic syndrome is particularly challenging due to the significant myelotoxicity associated with standard cytotoxic chemotherapy. Mirvetuximab soravtansine is an antibody-drug conjugate approved for use in platinum-resistant folate receptor alpha-positive high-grade ovarian cancer. Due to its limited myelotoxicity, it might be an interesting treatment option in patients with relevant haematologic side effects due to previous lines of chemotherapy. Case: We report on a patient with a recurrence of platinum-sensitive ovarian cancer (platinum-free interval: 16 months) who developed Myelodysplastic syndrome and ultimately, probably an acute Myeloid Leukaemia. Chemotherapy re-challenge with platinum-based combination chemotherapy was not feasible due to persistent thrombocytopenia (CTCAE grade 3). Therefore, treatment with mirvetuximab soravtansine was initiated showing durable response with a progression-free survival of nine months. The patient's platelet count and tumor marker CA125 remained stable for nine months while she was receiving antibody-drug conjugate treatment. Summary and conclusion: Patients with underlying haematologic disorders sometimes cannot receive platinum-based chemotherapy due to its haematotoxicity, raising the need for alternative treatments for recurrent high-grade ovarian cancer. Data from clinical trials, supported by our case, suggest that mirvetuximab soravtansine may provide a promising option, allowing durable response without worsening pre-existing thrombocytopenia.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.